诺和诺德,多了一个竞争对手

丁香园 Insight 数据库
Nov 11

一场让业内震惊的收购争夺战,终于落下帷幕:诺和诺德截胡失败,意味着它在减肥药领域又多了一个竞争对手。近期,医药行业上演了一出好戏:“宇宙大药厂”辉瑞与减肥药巨头诺和诺德打起来了,原因是为了争夺一家成立仅 3 年的下一代减肥药开发商 Metsera。本以为“诺华豪掷 120 亿美金收购 Avidity”已经够劲爆了,没想到辉瑞与诺和诺德的百亿美元竞购事件更加刺激。这场争夺战虽已落幕,但故事背后的逻辑...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10